Work

Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT).

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.8531

Authors: Michael S. Gordon, Harriet M. Kluger, Geoffrey Shapiro, Razelle Kurzrock, Gerald Edelman, Thomas A. Samuel, Ali H. Moussa, David A. Ramies, A. Douglas Laird, Frauke Schimmoller, Xiaodong Shen, Adil Daud

Institutions: Pinnacle Oncology Hematology, Yale Cancer Center, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Texas Oncology, Exelixis (United States), University of California, San Francisco

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2319216644

Cites:

Cited by: 19

Related to: 10